Clin Mol Hepatol > Volume 30(2); 2024 > Article
Tsai, Wu, and Hsu: Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
Dear Editor,
We sincerely appreciate the editorial by Drs. Huang and Tseng [1], commenting on our recent study published in Clinical and Molecular Hepatology [2] regarding the role of time-varying hepatitis B core-related antigen (HBcrAg) in predicting clinical relapse (CR) for chronic hepatitis B (CHB) patients who discontinued tenofovir or entecavir. We agree that nucleos(t) ide analogue (NA) cessation is generally safe with hepatitis B surface antigen (HBsAg) seroclearance [3], which is the only treatment endpoint widely acceptable across guidelines [4,5]. Unfortunately, it rarely occurs during long-term NA therapy [6]. Treatment discontinuation without first achieving HBsAg seroclearance invariably leads to recurrence of viremia and could precipitate hepatitis flare and even life-threatening acute on chronic liver failure [7]. The strategy of finite NA therapy, therefore, cannot be practiced without thorough consideration of the conceivable benefits and potential risks for an individual patient.
Substantial research efforts have been devoted to identify suitable candidates for finite NA therapy. Nevertheless, most predictors reported in the literature were host factors or viral biomarkers at or prior to treatment cessation [3]. Little is known about the risk assessment during the posttreatment monitoring. The risk could vary over time and the assessment may need to change accordingly to inform clinical management.
Our study demonstrated for the first time that serum HBcrAg levels as a time-varying predictor was more accurate than a fixed value in stratifying the risks of CR. This finding was further affirmed by multiple variable analyses adjusted for the serum level of HBsAg measured at treatment cessation, which was a validated biomarker associated with CR risks. Accordingly, our data suggest the most recent HBcrAg level is more predictive than a previous measurement to guide posttreatment monitoring. For the convenience of clinical application, the cutoff may be set at 1,000 U/mL to stratify distinct risks of CR.
Serum HBcrAg can only come from the covalently closed circular DNA (cccDNA) of HBV, in contrast to HBsAg which may also be produced via transcription of fragments of viral DNA integrated to host genome, particularly in the setting of long-term NA therapy [8]. This feature distinguishes the two circulatory viral markers with great implications for clinical utility. A growing body of literature has shown the potential of applying HBcrAg measurement in clinical practice as it may help predict HBeAg seroconversion, durability of NA therapy response, as well as the occurrence and recurrence of hepatocellular carcinoma [9,10]. In fact, prior studies including our own work, have shown that serum HBcrAg level at treatment cessation was useful to predict off-therapy relapses [11-13]. Our current study further expanded the potential utility of this biomarker, suggesting that serum HBcrAg not only be measured at treatment cessation but also during posttreatment follow-up.
As the editorialists point out, however, the commercial assay employed in the current study was not a sensitive one and unable to quantify serum HBcrAg levels below 1,000 U/mL. The current assay might fail to detect subtle fluctuations of serum HBcrAg after NA cessation. Consequently, it is not possible to appreciate the variability among HBcrAg levels lower than the detection limit and evaluate how it might correlate with clinical outcomes. This limitation could substantially compromise the usefulness of this biomarker particularly when more than half the patients in our study cohort had a serum HBcrAg level unquantifiable by the present assay. Although it is reasonable to classify patients with a HBcrAg level below 1,000 U/mL into a low-risk group, whether they can be more precisely risk stratified was unclear. Therefore, we agree with the editorialists that further research using more sensitive assay, such as the iTACT-HBcrAg [14], is needed to harness the full potential of HBcrAg measurement in clinical application.
We also concur with the editorialist’s insightful comment highlighting the importance of frequent HBV DNA measurement in the posttreatment monitoring. According to the updated Asian Pacific Association for the Study of the Liver (APASL) guidance, serum HBV DNA should be measured monthly for the initial 3 months after NA cessation, followed by bi-monthly or tri-monthly measurement, if viremia remains undetected [15]. This intensive early monitoring aims to promptly identify emerging viral breakthrough and early forecasts imminent hepatitis flares or even severe acute exacerbations.
We did not propose to replace HBV DNA by HBcrAg in the management of patients who stopped NA therapy. In our opinion, these two biomarkers play different yet complementary roles during the posttreatment monitoring. Nevertheless, we acknowledge that it was beyond the scope of the present study to investigate how the various predictors can be combined to optimize posttreatment monitoring of patients discontinuing NA therapy. More research is clearly warranted.
In summary, our study demonstrated the clinical relevance of measuring serum HBcrAg during the follow-up of patients who stop NA therapy, and found that the most recent level was more accurate than a previous measurement to predict CR. Although the commercial assay lacks the sensitivity to detect nuances of serum HBcrAg below the lower limit of detection ranges, a HBcrAg level below 1,000 U/mL may still serve as a clinically useful cutoff for predicting CR. A more sensitive assays with a broader range of detection may improve the clinical utility of HBcrAg and refine the risk assessment based on its dynamic measurement. Finally, it remains largely unknown how to incorporate various risk predictor for optimizing posttreatment monitoring. Our novel findings should call for further studies.


Authors’ contribution
Manuscript drafting: Ying-Nan Tsai, Yao-Chun Hsu. Manuscript edition and final approval: all authors.
Conflicts of Interest
Ying-Nan Tsai reported no conflicts of interest. Jia-Ling Wu reported no conflicts of interest. Yao-Chun Hsu has received research grants from Gilead Sciences, lecture fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, and Novartis, and has served as an advisory committee member for Gilead Sciences.


chronic hepatitis B
clinical relapse
end of treatment
hepatitis B core-related antigen
hepatitis B surface antigen
nucleos(t)ide analogue


1. Huang CT, Tseng TC. Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying HBcrAg. Clin Mol Hepatol 2024;30:154-156.
crossref pmid pdf
2. Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, et al. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. Clin Mol Hepatol 2024;30:98-108.
crossref pmid pmc pdf
3. Hsu YC, Tseng CH, Kao JH. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm. Clin Mol Hepatol 2023;29:869-890.
crossref pmid pmc pdf
4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398.
crossref pmid
5. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
crossref pmid pmc pdf
6. Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676-683.
crossref pmid
7. Hsu YC, Lin YH, Lee TY, Nguyen MH, Tseng CH, Ho HJ, et al. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study. Aliment Pharmacol Ther 2023;58:463-473.
8. Grudda T, Hwang HS, Taddese M, Quinn J, Sulkowski MS, Sterling RK, et al. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment. J Clin Invest 2022;132:e161818.
9. Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017;37:995-1001.
crossref pmid pdf
10. Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel) 2019;10:357.
crossref pmid pmc
11. Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther 2019;49:107-115.
crossref pmid pdf
12. Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4.
crossref pmid
13. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol 2022;76:1042-1050.
14. Inoue T, Watanabe T, Tanaka Y. Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy. Clin Mol Hepatol 2023;29:851-868.
crossref pmid pmc pdf
15. Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-851.
crossref pmid pdf

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail:
Copyright © The Korean Association for the Study of the Liver.         
TODAY : 1809
TOTAL : 1776734
Close layer